Cdc50B Inhibitors
Cdc50B inhibitors are a diverse group of compounds that can directly or indirectly affect the function of Cdc50B through specific signaling pathways or biological processes. Cdc50B, a type II membrane protein, is known to be involved in the trafficking of certain ATPases to the plasma membrane. Inhibitors such as Ouabain and Monensin disrupt ion homeostasis, which can indirectly inhibit Cdc50B by altering the essential ion balance necessary for its activity. Verapamil and Nifedipine, which are calcium channel blockers, can also indirectly inhibit Cdc50B by disrupting calcium-dependent cellular processes.
Brefeldin A and Tunicamycin act on protein transport and processing. Brefeldin A disrupts the structure of the Golgi apparatus and inhibits protein transport from the endoplasmic reticulum to the Golgi, indirectly inhibiting Cdc50B by inhibiting its proper trafficking to the cellular membrane. Tunicamycin inhibits N-linked glycosylation, a modification necessary for the proper folding and function of many proteins. As Cdc50B is a glycosylated protein, the inhibition of this process can lead to its functional impairment. Other inhibitors like Cyclosporine A, Phenylarsine Oxide, Thapsigargin, 2-Deoxy-D-glucose, Chlorpromazine, and Amiloride affect various aspects of cellular processes ranging from phosphatase activity, calcium homeostasis, glycolysis, and membrane properties to ion channels. Disruption in these processes leads to diminished functional activity of Cdc50B. For instance, cyclosporine A inhibits calcineurin, a calcium-dependent serine/threonine phosphatase, influencing protein trafficking and function and thereby indirectly impacting Cdc50B activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
Ouabain, a cardiac glycoside, inhibits the Na+/K+-ATPase pump, which is key to maintaining the ion gradients in cells. Inhibition of this pump can disrupt cellular homeostasis and indirectly inhibit Cdc50B by altering the essential ion balance necessary for its activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, inhibits the entry of calcium ions into cells. Given that calcium ions can play a role in the trafficking and function of proteins like Cdc50B, their decreased influx can indirectly inhibit Cdc50B activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus structure and inhibits protein transport from the endoplasmic reticulum to the Golgi. This can indirectly inhibit Cdc50B by preventing its proper trafficking to the plasma membrane where it functions. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is a sodium ionophore that disrupts the sodium ion balance within the cell. This can indirectly inhibit Cdc50B by altering the ion homeostasis necessary for its activity. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is a calcium channel blocker, which inhibits the entry of calcium ions into cells. This can indirectly inhibit Cdc50B activity by disrupting calcium-dependent cellular processes. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporine A inhibits calcineurin, a calcium-dependent serine/threonine phosphatase. As calcineurin can influence protein trafficking and function, its inhibition may indirectly impact Cdc50B activity. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, a modification necessary for the proper folding and function of many proteins. As Cdc50B is a glycosylated protein, the inhibition of this process can lead to its functional impairment. | ||||||
Phenylarsine oxide | 637-03-6 | sc-3521 | 250 mg | $41.00 | 4 | |
Phenylarsine Oxide is a tyrosine phosphatase inhibitor. By inhibiting phosphatases, it can potentially disrupt the phosphorylation state of proteins, including Cdc50B, thereby affecting their function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a non-competitive inhibitor of the sarco-/endoplasmic reticulum Ca2+ ATPase (SERCA). By inhibiting SERCA, it disrupts calcium homeostasis and can thereby indirectly inhibit Cdc50B. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose inhibits glycolysis by interfering with the enzyme hexokinase. Altered metabolic states can indirectly affect protein function, including Cdc50B. | ||||||